

REMARKS

Claims 1-19, 23-24, 26-27, and 34-35 were subject to restriction. Applicants elect without traverse Group I, directed to claims 1-9, 16, and 18-19. Applicants cancel claims 10-16, 23-24, 26-27, and 34-35 herein as being directed to non-elected subject matter but reserve the right to pursue non-elected subject matter in subsequent prosecution.

Applicants acknowledge the Examiner's statement on page 4 of the Action that in the event that Group I is elected, and claims therein are found allowable, it is likely that novelty would accrue to Group V and that Group V could be rejoined with Group I.

Claim 17 is amended herein to correct a typographical error to reflect its dependency from claim 1. In doing so, Applicants assume that claim 17 is grouped into Group I. However, if this is inaccurate, please inform the Applicants in the next Action.

Applicants were instructed to elect species related to a specific disorder to be treated, a specific cell type, a specific peptide, and a route of administration. Applicants elect the species of cancer as the specific disorder, cells that express one or more Hox genes as the cell type, SEQ ID NO:7 as the specific peptide species, and intravenous injection as the route of administration.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P03185US0.

Dated: September 4, 2007

Respectfully submitted,

By /Melissa L. Sistrunk/

Melissa L. Sistrunk
Registration No.: 45,579
FULBRIGHT & JAWORSKI L.L.P.
Fulbright Tower
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5151
(713) 651-5246 (Fax)
Agent for Applicant